Savient sells gout med to Crealta

Pending court approval, Savient's orphan drug Krystexxa will join Crealta Pharmaceuticals' drug portfolio.

Savient announced the deal for its refractory chronic gout medication Wednesday.

The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.